SCHEMBL1689504

SCHEMBL1689504

CN1CCN(Cc2cnn(-c3ccc(-c4ccccc4)cc3)c2-c2ccccc2F)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMO Q99835 4/20 0.45
DRD4 P21917 2/20 0.45
DRD3 P35462 2/20 0.45
DRD2 P14416 1/20 0.45
CHKA P35790 1/20 0.43
SSTR5 P35346 1/20 0.42
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
KDR P35968 1/20 0.41
HTR7 P34969 2/20 0.40
ACHE P22303 1/20 0.39
ALDH1A1 P00352 2/20 0.39
TNIK Q9UKE5 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
STAT1 P42224 1/20 0.38
HTT P42858 1/20 0.38
MAP4K1 Q92918 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7261049 0.96 CHKA (0.50) SMODRD4DRD3DRD2CHKA
SCHEMBL5737789 0.95 SMO (0.44) SMODRD4DRD3DRD2SSTR5
SCHEMBL7256544 0.94 DRD4 (0.44) SMODRD4DRD3DRD2CHKA
SCHEMBL5228638 0.93 DRD4 (0.41) SMODRD4DRD3DRD2SSTR5
SCHEMBL5224217 0.92 SMO (0.44) SMODRD4DRD3DRD2SSTR5
SCHEMBL2761085 0.92 DHODH (0.43) SMODRD4DRD3DRD2SSTR5
SCHEMBL7262116 0.91 SMO (0.45) SMODRD4DRD3DRD2SSTR5
SCHEMBL5227503 0.91 DRD4 (0.42) SMODRD4DRD3DRD2SSTR5
SCHEMBL5227102 0.90 LMNA (0.44) SMODRD4DRD3DRD2SSTR5
SCHEMBL5232121 0.90 DRD4 (0.39) SMODRD4DRD3DRD2SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003031435-A1 PYRAZOLE DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS MERCK PATENT GMBH (DE) 2003-04-17 WO claimed
US-20170172993-A1 Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. 2017-06-22 US disclosed
US-20170173009-A1 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. 2017-06-22 US disclosed
US-20170172993-A1 Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. 2017-06-22 US disclosed
US-20170173009-A1 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. 2017-06-22 US disclosed
US-9656955-B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2017-05-23 US disclosed
US-9656955-B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2017-05-23 US disclosed
US-9650334-B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2017-05-16 US disclosed
US-9650334-B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2017-05-16 US disclosed
US-9586945-B2 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG (DE) 2017-03-07 US disclosed
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott BmbH & Co. KG (DE) 2011-05-05 US disclosed
US-20110009378-A1 Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy ABBOTT GMBH & CO. KG (DE) 2011-01-13 US disclosed
US-20110009378-A1 Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy ABBOTT GMBH & CO. KG (DE) 2011-01-13 US disclosed
US-20100273739-A1 Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy ABBVIE INC. 2010-10-28 US disclosed
US-20100273739-A1 Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy ABBVIE INC. 2010-10-28 US disclosed
US-20100222346-A1 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-09-02 US disclosed
US-20100222346-A1 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-09-02 US disclosed
US-20060264419-A1 Substituted pyrazoles MERCK PATENT GMBH (DE) 2006-11-23 US disclosed
EP-1626967-A1 SUBSTITUTED PYRAZOLES MERCK PATENT GmbH (DE) 2006-02-22 EP disclosed
WO-2004089931-A1 SUBSTITUTED PYRAZOLES MERCK PATENT GMBH (DE) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170172993-A1 Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy AADAT, BCAT1, GFPT1 SMO 3345/4885DRD4 1042/4885DRD3 896/4885
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY GOLT1B, SLC10A1, SUGT1 SMO 2960/4885DRD4 3117/4885DRD3 2959/4885
US-20110009378-A1 Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy CYP11B2, CYP11B1, SLC10A1 SMO 1111/4885DRD4 2698/4885DRD3 2297/4885
US-20060264419-A1 Substituted pyrazoles HTR3A, HTR1A, HTR1D SMO 3049/4885DRD4 152/4885DRD3 57/4885
US-20100273739-A1 Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy AADAT, GFPT1, BCAT1 SMO 3140/4885DRD4 1879/4885DRD3 2107/4885
US-20100222346-A1 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY GDI2, GDI1, NQO2 SMO 2987/4885DRD4 2576/4885DRD3 3171/4885
US-20170173009-A1 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy SLC7A1, BCAT1, AADAT SMO 2945/4885DRD4 2544/4885DRD3 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.